Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Diabetesscreening in der Schwangerschaft vor Einführung eines generellen 75g oGTT
Saxer H, Rautenberg W, Fehr M, Lachat R, Eggimann T, Brühwiler H (2011). Diabetesscreening in der Schwangerschaft vor Einführung eines generellen 75g oGTT.
Jun 25, 2011Diabetesscreening in der Schwangerschaft vor Einführung eines generellen 75g oGTT
Jun 25, 2011Jahreskongress Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) 2011
Saxer Helene, Rautenberg W, Fehr M, Lachat R, Eggimann T, Brühwiler H
Erste Erfahrungen mit dem oralen75g- Glucosetoleranztest in der Schwangerschaft
Rautenberg W, Saxer H, Fehr M, Lachat R, Eggimann T, Brühwiler H (2011). Erste Erfahrungen mit dem oralen75g- Glucosetoleranztest in der Schwangerschaft. Presented at: Jahreskongress SGGG, Lugano
Jun 25, 2011Erste Erfahrungen mit dem oralen75g- Glucosetoleranztest in der Schwangerschaft
Jun 25, 2011Jahreskongress SGGG
Rautenberg W, Saxer Helene, Fehr M, Lachat R, Eggimann T, Brühwiler H
Erste Erfahrungen mit dem oralen75g- Glucosetoleranztest in der Schwangerschaft gemäss den Empfehlungen der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie
Rautenberg W, Saxer H, Fehr M, Lachat R, Eggimann T, Brühwiler H (2011). Erste Erfahrungen mit dem oralen75g- Glucosetoleranztest in der Schwangerschaft gemäss den Empfehlungen der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie. Presented at: Jahreskongress SGGG, Lugano
Jun 23, 2011Erste Erfahrungen mit dem oralen75g- Glucosetoleranztest in der Schwangerschaft gemäss den Empfehlungen der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie
Jun 23, 2011Jahreskongress SGGG
Rautenberg W, Saxer Helene, Fehr M, Lachat R, Eggimann T, Brühwiler H
Die Problematik der Enzymersatztherapie beim Morbus Pompe (Glykogenose Typ II)
Hundsberger T. Die Problematik der Enzymersatztherapie beim Morbus Pompe (Glykogenose Typ II) - Eine medizinische Einschätzung. Schweiz Med Forum 2011; 11:427-429.
Jun 22, 2011Die Problematik der Enzymersatztherapie beim Morbus Pompe (Glykogenose Typ II)
Jun 22, 2011Schweiz Med Forum 2011; 11:427-429
Hundsberger Thomas
Carbon dioxide insufflation in routine colonoscopy is safe and more comfortable: results of a randomized controlled double-blinded trial
Geyer M, Gueller U, Beglinger C. Carbon dioxide insufflation in routine colonoscopy is safe and more comfortable: results of a randomized controlled double-blinded trial. Diagn Ther Endosc 2011; 2011:378906.
Jun 15, 2011Carbon dioxide insufflation in routine colonoscopy is safe and more comfortable: results of a randomized controlled double-blinded trial
Jun 15, 2011Diagn Ther Endosc 2011; 2011:378906
Geyer M, Gueller Ulrich, Beglinger C
Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission
Mark M, Thürlimann B. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Med Oncol 2011
Jun 12, 2011Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission
Jun 12, 2011Med Oncol 2011
Mark Michael, Thürlimann Beat
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011
Jun 12, 2011Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
Jun 12, 2011Breast Cancer Res Treat 2011
von Minckwitz Gunter, Untch Michael, Diebold Kurt, Tiemann Katharina, Hoffmann Gerald, Henschen Stephan, Schrader Iris, Hanusch Claus, Clemens Michael R, Just Marianne, Dietrich Klaus, Eidtmann Holger, Holms Frank, Solbach Christine, Tesch Hans, Huober Jens, Loibl Sibylle, Darb-Esfahani Silvia, Denkert Carsten
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Jörger M, Huitema A, Illerhaus G, Ferreri A. High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?. Leuk Lymphoma 2011; 52:1825-7.
Jun 10, 2011High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Jun 10, 2011Leuk Lymphoma 2011; 52:1825-7
Jörger Markus, Huitema A D R, Illerhaus G, Ferreri A J M
The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
Früh M. The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. Lung Cancer 2011; 72:265-270.
Jun 1, 2011The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
Jun 1, 2011Lung Cancer 2011; 72:265-270
Früh Martin
Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Regan M, Price K, Giobbie-Hurder A, Thürlimann B, Gelber R, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 2011; 13:209.
May 26, 2011Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
May 26, 2011Breast Cancer Res 2011; 13:209
Regan Meredith M, Price Karen N, Giobbie-Hurder Anita, Thürlimann Beat, Gelber Richard D, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group
The evaluation of the autonomic nervous system using the Finometer Pro device and sympathetic skin response (SSR): Results in 141 consecutive patients
Vehoff J, Hägele-Link S, Hundsberger T, Tettenborn B (2011). The evaluation of the autonomic nervous system using the Finometer Pro device and sympathetic skin response (SSR): Results in 141 consecutive patients. Presented at: Jahrestagung der Schweizerischen Gesellschaft für klinische Neurophysiologie (SGKN), Luzern
May 20, 2011The evaluation of the autonomic nervous system using the Finometer Pro device and sympathetic skin response (SSR): Results in 141 consecutive patients
May 20, 2011Jahrestagung der Schweizerischen Gesellschaft für klinische Neurophysiologie (SGKN)
Vehoff Jochen, Hägele-Link Stefan, Hundsberger Thomas, Tettenborn Barbara
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.
May 18, 2011Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
May 18, 2011Cancer Chemother Pharmacol 2011; 69:25-33
Jörger Markus, Beijnen J H, Huitema A D R, Rosing H, Vainchtein L D, Jansen R S, Smits P H M, Doodeman V D, Baas P, Burgers J A, Schellens J H M
Dying as a Transition
Renz M (2011). Dying as a Transition. Presented at: 12th Congress of the European Association of Palliative Care (EAPC), Lissabon
May 18, 2011Dying as a Transition
May 18, 201112th Congress of the European Association of Palliative Care (EAPC)
Renz Monika
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Joly F, Huober J, Dell'Anna T, Ferrandina G, Vergote I, Reinthaller A, Vaughan M, Sugimoto A, Boman K, Donoghoe M, Fabbro M, Ray-Coquard I, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011; 122:226-32.
May 14, 2011Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
May 14, 2011Gynecol Oncol 2011; 122:226-32
Joly Florence, Huober Jens, Dell'Anna Tiziana, Ferrandina Gabriella, Vergote Ignace, Reinthaller Alexander, Vaughan Michelle, Sugimoto Akira, Boman Karin, Donoghoe Mark, Fabbro Michel, Ray-Coquard Isabelle, Pujade-Lauraine Eric
Pseudoangiomatous stromal hyperplasia of breast in man: a case report
Bolla D, Bolla N, Öhlschlegel C, Schoening A, Stickel J, Thürlimann B, Hornung R. Pseudoangiomatous stromal hyperplasia of breast in man: a case report. Breast J 2011; 17:311-2.
May 7, 2011Pseudoangiomatous stromal hyperplasia of breast in man: a case report
May 7, 2011Breast J 2011; 17:311-2
Bolla Daniele, Bolla Nicole, Öhlschlegel Christian, Schoening Andrea, Stickel Juliane, Thürlimann Beat, Hornung René
Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients
Viehl C, Langer I, Gueller U, Zanetti-Dällenbach R, Moch H, Wight E, Oertli D, Zuber M. Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. J Surg Oncol 2011; 103:531-3.
May 1, 2011Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients
May 1, 2011J Surg Oncol 2011; 103:531-3
Viehl Carsten T, Langer Igor, Gueller Ulrich, Zanetti-Dällenbach Rosanna, Moch Holger, Wight Edward, Oertli Daniel, Zuber Markus
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
Jörger M, deJong D, Burylo A, Burgers J, Baas P, Huitema A, Beijnen J, Schellens J. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011; 74:310-7.
Apr 29, 2011Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
Apr 29, 2011Lung Cancer 2011; 74:310-7
Jörger Markus, deJong D, Burylo A, Burgers J A, Baas P, Huitema A D R, Beijnen J H, Schellens J H M
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
von Minckwitz G, Zahm D, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, du Bois A, Blohmer J, Müller B, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7.
Apr 25, 2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
Apr 25, 2011J Clin Oncol 2011; 29:2150-7
von Minckwitz Gunter, Zahm Dirk-Michael, Khandan Fariba, Hoffmann Gerald, Gerber Bernd, Eidtmann Holger, Fend Falko, Dietel Manfred, Mehta Keyur, du Bois Andreas, Blohmer Jens Uwe, Müller Berit Maria, Loibl Sibylle, Budczies Jan, Hanusch Claus, Darb-Esfahani Silvia, Hilfrich Jörn, Weiss Erich, Huober Jens, Denkert Carsten
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
Apr 18, 2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Apr 18, 2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael
Adhärenz und Sicherheit bei oraler Tumortherapie
Rothermundt C. Adhärenz und Sicherheit bei oraler Tumortherapie. Swiss Medical Forum 2011; 11:276-278.
Apr 14, 2011Adhärenz und Sicherheit bei oraler Tumortherapie
Apr 14, 2011Swiss Medical Forum 2011; 11:276-278
Rothermundt Christian